Wechselwirkungen · Kerendia
Kerendia 10 mg film-coated tablets Kerendia 20 mg film-coated tablets Kerendia 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-145308 · Präparat HOS-099328
At 40 mg once daily, finerenone is a weak inhibitor of the CYP2C8 enzyme in vivo. Co-administration of multiple doses of 40 mg finerenone with the CYP2C8 probe substrate repaglinide resulted in a 1.59-fold increase in mean repaglinide AUC and a 1.30-fold increase in Cₘₐₓ. The potentially increased exposure of CYP2C8 substrates with a narrow therapeutic window needs to be considered when used concomitantly with finerenone 40 mg once daily. A single dose of 20 mg finerenone had no clinically relevant effect on AUC and Cₘₐₓ of the CYP2C8 probe substrate repaglinide. Thus, finerenone does not inhibit CYP2C8 at this dose level.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): repaglinide (HOS-086935)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T09:57:00Z · SHA-256 98ba233d390b44b94791f7f65cd1eff51a109db99630ace3897a132ef234b558 · Passage e5562636d91ce3551505d25b6d5ae379ed10c7eac520b8736999b3572b7a8427 · Zeichen 3962–4592 im Abschnitt